Finance & Capital Markets

  1. Picking Biotech Jockeys With SR One's Simeon George, M.D. 9/15/2024

    SR One Capital Management CEO Simeon George, M.D. has a seemingly innate ability to pick winning biotech builders. On the Business of Biotech, Dr. George shares insight into the decision-making processes that have contributed to his success at picking winners as an investment banker and biotech venture capitalist. Listen now!

  2. Art Of The Pivot With Elevation Oncology's Joe Ferra 1/3/2024

    Relatively new CEO Joseph Ferra has orchestrated some pretty significant change at Elevation Oncology in the two(ish) years since the Business of Biotech last hosted the company. In that short time, Ferra advanced from CFO to CEO, a move that aligned very closely with the company's difficult decision to shelve the late phase 2 anti-HER3 monoclonal antibody candidate it was founded on.

  3. BoB@JPM: Tom Chalberg, Ph.D., Genascence 2/23/2025

    This episode of the Business of Biotech finds Matt Pillar and Ben Comer exploring the evolution of gene therapy with Dr. Tom Chalberg, Founder, Chairman, & CEO at Genascence. Listen in as they discuss ATMPS' transition from treating rare diseases to addressing common conditions like osteoarthritis, share insights on the delivery mechanism and regulatory challenges in the space, and get into the nuts and bolts of the Genascence partnership strategy. 

  4. The Implications Of China's Growing Biotech Industry With Allan Shaw 4/16/2025

    Business of Biotech MVP Allan Shaw is back to talk about the rise of China's biotech sector, and its evolution from fast follower to global innovation powerhouse.

  5. Biopharma Comebacks With Vincerx's Ahmed Hamdy, MD 6/28/2023

    Ahmed Hamdy, MD didn’t ask to be the subject of Nathan Vardi's new book​ For Blood and Money: Billionaires, Biotech, and the Quest for a Blockbuster Drug. In fact, he’d rather not relive that chapter.

  6. BoB@JPM: Peter Anastasiou, Capsida Biotherapeutics 2/9/2025

    From the JP Morgan Healthcare Conference in San Francisco, Peter Anastasiou, CEO of Capsida Biotherapeutics, discusses his journey from big pharma to biotech and the challenges he faces on the leading edge of first-generation gene therapies.

  7. Funding A Neurodegeneration Startup With Coya Therapeutics' Howard Berman 5/10/2023

    Like many of us, Howard Berman, Ph.D. has personal experience with the tragedy of cognitive decline. Neurodegenerative disorders are on the rise, and when one afflicted his father — a triple board-certified physician — he saw firsthand that they don't discriminate. Berman has dedicated his career to addressing neuro, autoimmune, and metabolic diseases, having founded Nicoya Health in 2020 and overseeing its merger with Coya Therapeutics the following year. The company came out of the gates this year fueled by an 11th-hour 2022 IPO, one of just a dozen on the year. Berman joined the Business of Biotech to share his strategy during a stingy stretch in biotech capital markets. 

  8. The Year's Top Stories With Allan Shaw 12/26/2021

    Join your host Matt Pillar and guest Allan Shaw for a no-holds-barred retrospective on the year's top stories and trends. From the frontlines of the COVID-19 pandemic to the questionable approval of Aduhelm to leadership instability at the FDA and more, Shaw dissects the year past and predicts how those stories will influence the biotech industry in 2022 and beyond.

  9. IL-2 Program Profits With Bonum's Drs. John Mulligan And Neela Patel 12/13/2023

    On this week's episode of the Business of Biotech, we welcome two extraordinary guests - Dr. Neela Patel, a molecular biologist-turned-Chief Business Officer, and Dr. John Mulligan, an academic-turned-founder of newly-formed Bonum Therapeutics. Together, Neela and John will pull back the curtain on Bonum's transition from its predecessor, Good Therapeutics, which was fueled by a high-profile asset sale to Roche.

  10. Building A Cancer Pipeline In A Molecule With Actuate Therapeutics' Dan Schmitt 11/26/2025

    On this week's episode of the Business of Biotech, Dan Schmitt, President and CEO at Actuate Therapeutics, talks about building a company around elraglusib, a GSK-3β inhibitor for cancer.